Sun Pharma has received FDA approval for its ophthalmology NDA, BromSite (0.075% bromfenac), the first such non-steroidal anti-inflammatory drug (NSAID ) cleared by the agency to prevent pain and treat inflammation in cataract surgery patients.
Sun Set For US Eye-care Push With BromSite Approval
Sun Pharma has received FDA approval for its ophthalmology NDA, BromSite (0.075% bromfenac), the first such non-steroidal anti-inflammatory drug (NSAID ) cleared by the agency to prevent pain and treat inflammation in cataract surgery patients.
More from Musculoskeletal
More from Therapy Areas
• By
Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.
• By
The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.
• By
Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.